ChromaDex Gets Orphan Designation Status From FDA For Nicotinamide Riboside Chloride For Treatment Of Ataxia Telangiectasia
Portfolio Pulse from Benzinga Newsdesk
ChromaDex has received Orphan Drug Designation from the FDA for its Nicotinamide Riboside Chloride for the treatment of Ataxia Telangiectasia.
June 03, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ChromaDex has received Orphan Drug Designation from the FDA for its Nicotinamide Riboside Chloride for the treatment of Ataxia Telangiectasia. This designation could lead to market exclusivity and potential financial incentives.
The FDA's Orphan Drug Designation is significant as it provides market exclusivity, tax credits, and potential grants, which can positively impact ChromaDex's financials and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100